This SensoLyte® high-sensitivity (2 pg/ml) beta-Amyloid (1-42) Quantitative ELISA Kit (Human) is optimized to detect human beta-Amyloid (1-42) peptide in human brain lysate, transgenic mouse brain lysate, human cerebrospinal fluid, plasma, or saliva. Wells are pre-coated with monoclonal anti-beta-Amyloid (1-42) specific capture antibodies and blocked with a proprietary blocking solution. The amount of human beta-Amyloid (1-42) is quantified using ELISA. Ample materials and reagents are provided to perform 96 assays.
Alzheimer's Disease (AD) is the most common neurodegenerative disorder in elderly people. It has been demonstrated that AD has biological causes and is characterized by the presence of senile plaques and neurofibrillary tangles mainly in cerebral cortex and hippocampus brain regions. Beta-Amyloid (1-40) (Aα40) and beta-Amyloid (1-42) (Aα42) are the main components of the above plaques; however, other forms of beta-Amyloid peptides are also present. Both peptides are cleaved from the Amyloid Precursor Protein (APP) by α-secretase and γ-secretase enzymes. Many studies suggest that Aα42 or/and Aα43 are required to initiate formation of amyloid plaques and neurofibrills that leads to the neurodegeneration, while Aα40 is less neurotoxic.